Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer
Abstract Breast cancer is the most common malignancy in women and a public health problem worldwide. Breast cancer is often accompanied by an inflammatory process characterized by the presence of proinflammatory cytokines such as tumor necrosis factor (TNF-α), which has important implications in the...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-12-01
|
| Series: | Journal of Biomedical Science |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12929-017-0398-9 |
| _version_ | 1818543608028987392 |
|---|---|
| author | Isela Martínez-Reza Lorenza Díaz Rocío García-Becerra |
| author_facet | Isela Martínez-Reza Lorenza Díaz Rocío García-Becerra |
| author_sort | Isela Martínez-Reza |
| collection | DOAJ |
| description | Abstract Breast cancer is the most common malignancy in women and a public health problem worldwide. Breast cancer is often accompanied by an inflammatory process characterized by the presence of proinflammatory cytokines such as tumor necrosis factor (TNF-α), which has important implications in the course of the disease. Inflammation has been described primarily as a favorable environment for tumor development. However, under certain conditions TNF-α can promote signals for activation, differentiation, survival or cell death, so the study of the variants of this cytokine, its receptors, the presence of polymorphisms and its implication in different phenotypes of breast cancer is necessary. Although the clinical application of TNF-α has been limited by its toxicity and side effects, preclinical and clinical studies have shown that these effects may partially be avoided via tumor-targeted delivery strategies. In this manner, TNF-α alone or combined with chemotherapy and radiotherapy can function as an adjuvant in the treatment of breast cancer. |
| first_indexed | 2024-12-11T22:37:37Z |
| format | Article |
| id | doaj.art-3956cd0e2deb43929375a8aebb1df997 |
| institution | Directory Open Access Journal |
| issn | 1423-0127 |
| language | English |
| last_indexed | 2024-12-11T22:37:37Z |
| publishDate | 2017-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Biomedical Science |
| spelling | doaj.art-3956cd0e2deb43929375a8aebb1df9972022-12-22T00:47:54ZengBMCJournal of Biomedical Science1423-01272017-12-012411810.1186/s12929-017-0398-9Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancerIsela Martínez-Reza0Lorenza Díaz1Rocío García-Becerra2Departamento de Biología de la Reproducción, Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránDepartamento de Biología de la Reproducción, Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránDepartamento de Biología de la Reproducción, Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránAbstract Breast cancer is the most common malignancy in women and a public health problem worldwide. Breast cancer is often accompanied by an inflammatory process characterized by the presence of proinflammatory cytokines such as tumor necrosis factor (TNF-α), which has important implications in the course of the disease. Inflammation has been described primarily as a favorable environment for tumor development. However, under certain conditions TNF-α can promote signals for activation, differentiation, survival or cell death, so the study of the variants of this cytokine, its receptors, the presence of polymorphisms and its implication in different phenotypes of breast cancer is necessary. Although the clinical application of TNF-α has been limited by its toxicity and side effects, preclinical and clinical studies have shown that these effects may partially be avoided via tumor-targeted delivery strategies. In this manner, TNF-α alone or combined with chemotherapy and radiotherapy can function as an adjuvant in the treatment of breast cancer.http://link.springer.com/article/10.1186/s12929-017-0398-9TNF-αTNFR1TNFR2Breast cancer |
| spellingShingle | Isela Martínez-Reza Lorenza Díaz Rocío García-Becerra Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer Journal of Biomedical Science TNF-α TNFR1 TNFR2 Breast cancer |
| title | Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer |
| title_full | Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer |
| title_fullStr | Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer |
| title_full_unstemmed | Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer |
| title_short | Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer |
| title_sort | preclinical and clinical aspects of tnf α and its receptors tnfr1 and tnfr2 in breast cancer |
| topic | TNF-α TNFR1 TNFR2 Breast cancer |
| url | http://link.springer.com/article/10.1186/s12929-017-0398-9 |
| work_keys_str_mv | AT iselamartinezreza preclinicalandclinicalaspectsoftnfaanditsreceptorstnfr1andtnfr2inbreastcancer AT lorenzadiaz preclinicalandclinicalaspectsoftnfaanditsreceptorstnfr1andtnfr2inbreastcancer AT rociogarciabecerra preclinicalandclinicalaspectsoftnfaanditsreceptorstnfr1andtnfr2inbreastcancer |